Aethlon Medical (NASDAQ:AEMD) Stock Price Passes Below Two Hundred Day Moving Average of $1.21

Shares of Aethlon Medical, Inc. (NASDAQ:AEMDGet Rating) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.21 and traded as low as $0.95. Aethlon Medical shares last traded at $0.98, with a volume of 291,528 shares traded.

Analyst Ratings Changes

Separately, upgraded shares of Aethlon Medical to a “sell” rating in a report on Friday, August 12th.

Aethlon Medical Price Performance

The stock has a market capitalization of $16.22 million, a price-to-earnings ratio of -1.34 and a beta of 0.75. The stock’s 50 day simple moving average is $1.17 and its 200-day simple moving average is $1.21.

Aethlon Medical (NASDAQ:AEMDGet Rating) last posted its earnings results on Tuesday, June 28th. The medical equipment provider reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.13). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $1.02 million. Aethlon Medical had a negative net margin of 3,542.86% and a negative return on equity of 59.57%. As a group, equities research analysts anticipate that Aethlon Medical, Inc. will post 0.59 earnings per share for the current fiscal year.

Institutional Trading of Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Natixis bought a new stake in Aethlon Medical, Inc. (NASDAQ:AEMDGet Rating) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 25,000 shares of the medical equipment provider’s stock, valued at approximately $28,000. Natixis owned about 0.15% of Aethlon Medical as of its most recent SEC filing. 5.94% of the stock is owned by institutional investors.

About Aethlon Medical

(Get Rating)

Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes.

Further Reading

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with's FREE daily email newsletter.